introduction
In Japan, the incidence of colorectal cancer (CRC) has increased nearly fivefold in the last 25 years, owing primarily to changing Japanese dietary habits, which are becoming increasingly similar to those of Western countries. In 2008, there were 101 656 new cases of CRC in Japan and 43 349 deaths attributed to this disease [1] . CRC is now the second most common malignancy in Japan and is predicted to become the most common by 2015. Fluorouracil (5-FU) was one of the first chemotherapies used for the treatment of CRC, and the combination of 5-FU with leucovorin and oxaliplatin (FOLFOX) has improved outcomes. Treatment with these components (plus irinotecan in some regimens) can provide a median overall survival (OS) of up to 20 months, compared with 6 months with best supportive care [2] . Japanese clinical guidelines recommend FOLFOX as standard treatment of metastatic colorectal cancer (mCRC) [3] . To reduce toxicity associated with the FOLFOX regimen, a number of modifications have been tried [4, 5] ; the current standard is modified FOLFOX6 (mFOLFOX6).
Inhibition of the vascular endothelial growth factor (VEGF) signalling pathway with bevacizumab has demonstrated additional clinical benefit in CRC when used with 5-FU-based regimens in the first-line setting in mCRC [6, 7] . Cediranib is an oral highly potent VEGF tyrosine kinase inhibitor (TKI) that inhibits all three VEGF receptors [8, 9] . Cediranib is suitable for once-daily dosing and has demonstrated antitumour activity during early phase clinical evaluation in patients with advanced cancer [10] . Further studies demonstrated that cediranib was generally well tolerated as monotherapy [11] [12] [13] [14] [15] and in combination with various anticancer agents at doses £30 mg/day [16] [17] [18] [19] [20] [21] .
The efficacy of cediranib in combination with chemotherapy has been investigated in two phase III studies-HORIZON II [22] and HORIZON III [23] -in Western patients with previously untreated mCRC. Two cediranib doses were initially selected for investigation in the HORIZON programme: 20 (lowest biologically active dose) and 30 mg/day (maximum dose suitable for chronic dosing in combination with chemotherapy). The decision to investigate cediranib 20 and 30 mg/day doses in this study was taken before an end-of-phase II decision from the HORIZON programme to proceed with only the 20 mg/day dose. As such, this two-part phase I/II study, which mirrored HORIZON II, investigated cediranib, at the same doses used initially in the Western studies, plus mFOLFOX6 in Japanese patients with previously untreated mCRC (ClinicalTrials.gov identifier NCT00494221; AstraZeneca study code D8480C00039). The phase I part of this study demonstrated that both doses of cediranib were generally well tolerated in combination with mFOLFOX6 [24] . Here, we report the results of the randomised, double-blind, phase II part of this study, which assessed the efficacy of cediranib (20 or 30 mg/day) plus mFOLFOX6 compared with mFOLFOX6 alone.
patients and methods
eligibility Eligible patients were aged ‡18 years with histological or cytological confirmation of carcinoma of the colon or rectum. Patients required chemotherapy for stage IV (metastatic) disease, had a World Health Organisation (WHO) performance status (PS) of zero or one, and one or more measurable lesions according to the RECIST (version 1.0). Any adjuvant oxaliplatin or 5-FU therapy must have been completed >12 and >6 months, respectively, before study entry. Patients with brain or meningeal metastases were considered eligible if they were clinically stable and had not required corticosteroid treatment of 10 days. Exclusion criteria included prior systemic therapy for metastatic disease and prior therapy with monoclonal antibodies or small molecule inhibitors against VEGF or VEGF receptors, including bevacizumab and cediranib.
study design
This phase II, randomised, double-blind, placebo-controlled study assessed the efficacy of first-line treatment with cediranib plus mFOLFOX6 compared with mFOLFOX6 alone. Patients were randomised 1 : 1 : 1 to receive once-daily cediranib (20 . Randomised treatment was continued until objective disease progression (as defined by RECIST) or until the occurrence of toxicity, death, withdrawal of patient consent or other discontinuation criteria. RECIST measurements were made using computed tomography or magnetic resonance imaging scans; clinical assessment of these scans was conducted by the study investigators. The primary objective was to determine the efficacy of cediranib plus mFOLFOX6 compared with mFOLFOX6 alone by assessment of progression-free survival (PFS). Secondary objectives included comparison of OS, objective response rate (ORR: complete response + partial response), duration of response, change in tumour size and assessment of the safety and tolerability of cediranib plus mFOLFOX6. An exploratory end point was to investigate the effect of treatment on soluble markers of angiogenesis (VEGF and sVEGFR-2). VEGF and sVEGFR-2 were measured by enzymelinked immunosorbent assay of plasma samples from patients who provided separate informed consent.
PFS and ORR were determined from objective tumour assessments (RECIST) carried out at weeks 6, 12, 18, 24 and then every 12 weeks until disease progression or death. Adverse events (AEs) were recorded and graded according to Common Terminology Criteria for Adverse Events version 3.0. The study was approved by each centre's institutional review board and was carried out in accordance with the Declaration of Helsinki, the International Conference on Harmonisation/Good Clinical Practice, applicable regulatory requirements and the AstraZeneca policy on Bioethics.
statistical analysis
Assuming a median PFS of 9 months in the placebo group, an 18-month accrual period and a minimum 12-month follow-up, a total of 55 patients per group was required to have 80% power to detect a true PFS hazard ratio (HR) of 0.6 at two-sided significance level of P < 0.2 (one-sided P < 0.1), which was considered appropriate evidence of activity for a randomised phase II study [25] . The primary PFS analysis was conducted using a log-rank test stratified by WHO PS (0 or 1) and a two-level baseline liver function covariate (covariate 1 for baseline albumin < 3.5 g/l or ALP > 320 U/l; covariate 0 for all other values). PFS and OS were summarised by treatment group using the Kaplan-Meier method. The formal analysis was conducted when 105 progression events had occurred across the three groups. No formal statistical analysis was carried out on safety data.
The results in the present study were relatively immature (65% of PFS events versus 81% in HORIZON II) and the HR was favourable compared with HORIZON II (HR = 0.84). Furthermore, there was a higher proportion of patients with a PS of zero. Therefore, further analysis of efficacy and safety outcomes was carried out when 81% of progression events had occurred. (Table 1 ). All patients were Japanese and 20% were receiving antihypertensive treatment at baseline. Baseline characteristics were generally well balanced across the groups, although there were more female patients in the cediranib 30 mg group. Imbalances were noted in metastases at baseline, time from initial diagnosis to randomisation, tumour grading, baseline ALP and baseline liver function (Table 1) . At the protocolled data cut-off (13 October 2009), 65% (112) of patients had progressed and 22% (38) had died. The most common reason for discontinuation of placebo/cediranib was worsened condition. At the second data cut-off (11 June 2010), 81% of patients had progressed and median OS follow-up was 19.0 months with 74 OS events.
efficacy For the PFS comparison of cediranib 20 mg versus placebo, the HR was 0.70 [95% confidence interval (CI) 0.44-1.11], two-sided P = 0.167 (Figure 2A) , which met the protocoldefined criterion for evidence of activity (P < 0.2). Median PFS was 10.2 and 8.3 months, respectively. For the PFS comparison of cediranib 30 mg versus placebo, the HR was 0.82 (95% CI 0.54-1.31), two-sided P = 0.261 ( Figure 2B ), which did not meet the predefined criterion. Median PFS was 8.9 months in the cediranib 30 mg arm. Predefined subgroup analysis of PFS for both dose groups did not identify a particular patient original articles
Annals of Oncology population that derived a differential PFS benefit from cediranib versus placebo (supplemental Figure S1 , available at Annals of Oncology online). The ORR was 53.4%, 69.6% and 53.4% in the cediranib 20 mg, cediranib 30 mg and placebo arms, respectively; RECIST best response is summarised in Table 2 . The median best percentage changes in tumour size were 237.3% (cediranib 20 mg), 243.4% (cediranib 30 mg) and 240.0% (placebo). The median duration of response was 9.2 (cediranib 20 mg), 6.7 (cediranib 30 mg) and 7.1 months (placebo) (Figure 3) . At the primary analysis, there were insufficient deaths (total = 38; 15, 9 and 14 in the cediranib 20 mg, cediranib 30 mg and placebo arms, respectively) to draw conclusions on OS.
safety and tolerability
Overall, the most common AEs were diarrhoea and hypertension (Table 3) ; neither caused discontinuation of cediranib at the 20 mg dose. The incidence of AEs leading to discontinuation of cediranib/placebo was higher in the cediranib 30 mg group (27%) compared with the cediranib 20 mg (19%) or placebo (0%) groups; of these, only decreased original articles Annals of Oncology appetite, diarrhoea and pneumonia (all n = 2) were reported in multiple patients. The incidence of grade 3/4 AEs was 66%, 75% and 36% in the cediranib 20 mg, cediranib 30 mg and placebo groups, respectively. The most common grade 3/4 AEs are summarised in Table 4 . The incidence of serious adverse events (SAEs) was 39.7%, 39.3% and 19.0% in the cediranib 20 mg, cediranib 30 mg and placebo groups, respectively. No AEs had an outcome of death.
Clinical laboratory evaluation showed that treatment with cediranib plus mFOLFOX6 caused decreases in leucocyte, neutrophil and platelet counts and an increase in thyroidstimulating hormone, but no new clinically important trends were observed in either cediranib group.
The median duration of exposure was 241.5, 213.0 and 223.5 days in the cediranib 20 mg, cediranib 30 mg and placebo groups, respectively. The proportion of patients experiencing a dose reduction/pause was highest in the cediranib 30 mg group (83.9%) versus the cediranib 20 mg (79.3%) and placebo (56.9%) groups (supplemental Figure  S2 , available at Annals of Oncology online). The dose intensity of cediranib/placebo was lower in the 30 mg group compared with the 20 mg and placebo groups; the mean daily dose of cediranib was 16.6 and 22.8 mg in the cediranib 20 and 30 mg groups, respectively. Exposure to mFOLFOX6 was similar in all arms; the median numbers of cycles of 5-FU, leucovorin and oxaliplatin were 17.0, 17.0 and 12.5, respectively, in the cediranib 20 mg group, 14.0, 14.0 and 11.0, respectively, in the cediranib 30 mg group and 15.0, 15.0 and 11.5, respectively, in the placebo group. However, more patients in the cediranib 30 mg group (33%) stopped oxaliplatin >12 weeks before progression compared with those in the cediranib 20 mg (14%) or placebo (8%) groups.
soluble biomarkers
Median VEGF levels ranged from 47 to 55 pg/ml at baseline; during treatment, levels remained similar to baseline in the placebo group but increased in cediranib-treated patients. In the cediranib 20 mg group, levels increased to 89 pg/ml by day 28 and to 130 pg/ml thereafter. In the cediranib 30 mg group, levels increased to 160-170 pg/ml from days 28 to 84 before decreasing to 151 pg/ml by day 112.
Median sVEGFR-2 levels ranged from 9095 to 10 126 pg/ml at baseline. In the placebo group, median levels decreased to 7204 pg/ml on day 112. In the cediranib 20 mg group, median levels decreased to 7091 pg/ml on day 28 and 6403 pg/ml on day 112. The corresponding median levels in the cediranib 30 mg group were 5836 and 5789 pg/ml.
extended follow-up
At second data cut-off, PFS events had been observed in 47 (81%), 46 (82%) and 46 (79%) patients in the cediranib 20 mg, cediranib 30 mg and placebo groups, respectively. The PFS HR for the cediranib 20 mg group versus placebo was 0.76 (95% CI 0.51-1.15), two-sided P = 0.0879. Median PFS was 10.9 and 8.3 months, respectively. In the cediranib 20 mg group, 40.5% of patients were event free at 12 months compared with 28.9% in the placebo group. The PFS comparison for cediranib 30 mg versus placebo was 0.96 (95% CI 0.64-1.46), two-sided P = 0.429. Median PFS was 9.8 and 8.3 months, respectively, and 36.1% of patients were event free at 12 months in the cediranib 30 mg group versus 28.9% in the placebo group.
At final data cut-off, 24 (41.4%), 27 (48.2%) and 23 (39.7%) patients had died in the cediranib 20 mg, cediranib 30 mg and placebo groups, respectively. For the comparison of cediranib 20 mg versus placebo, the HR was 1.09 (95% CI 0.61-1.95), two-sided P = 0.543; median OS was not reached in the cediranib 20 mg group. For the comparison of cediranib 30 mg versus placebo, the HR was 1.28 (95% CI 0.73-2.24), two-sided P = 0.706. Median OS was 22.4 and 23.3 months in the cediranib 30 mg and placebo groups, respectively.
discussion
Patients enrolled in this study were representative of the target population of Japanese patients with previously untreated mCRC and consistent with previous studies [26, 27] . Although baseline characteristics were generally well balanced across the three groups, imbalances were noted. The imbalances in ALP and albumin levels probably occurred because the data were analysed at a central laboratory, whereas stratification according to baseline liver function was carried out in individual centres.
The median PFS of patients who received mFOLFOX6 alone in this study (8.3 months) was consistent with the SWIFT-2 (8.2 months) [27] and TREE-1 (8.7 months) [28] studies, in 
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which patients received mFOLFOX6 as first-line treatment of mCRC. Furthermore, the median PFS of patients in this study who received cediranib 20 mg plus mFOLFOX6 (10.2 months) compares well with the time to progression (9.9 months) for patients who received bevacizumab plus mFOLFOX6 in the TREE-2 study [28] . It is worth noting that TREE-2 was conducted in non-Japanese patients and there is a lack of phase III data for bevacizumab plus FOLFOX in the first-line setting in Japanese mCRC patients. A recent phase I/II study of first-line therapy comprising capecitabine plus oxaliplatin (XELOX) and bevacizumab in 64 Japanese patients with mCRC revealed a median PFS of 11 months, although the primary end points of this study were safety and ORR [29] . Here, the higher response rate observed in patients treated with cediranib 30 mg compared with the other arms did not translate into prolonged PFS, possibly due to differences in tolerability profiles of the cediranib arms. More patients in the cediranib 30 mg group experienced AEs (in particular, grade 3/4 diarrhoea) that led to discontinuation, dose reduction or dose interruption, than in the cediranib 20 mg or placebo groups. This appeared to impact on chemotherapy delivery-patients in the 30 mg arm received a lower dose intensity of oxaliplatin, which may reflect the differences in PFS outcomes. Due to these differences in tolerability, results from this study suggest that cediranib 20 mg is more suitable than 30 mg for long-term dosing in combination with mFOLFOX6 in Japanese patients with previously untreated mCRC. Cediranib 20 mg plus mFOLFOX6 was generally well tolerated, although the incidence of SAEs was higher compared with the placebo group. The most frequently reported AEs for the combination of cediranib 20 mg and mFOLFOX6 were diarrhoea and hypertension. The >50% incidence of palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome) in patients who received cediranib is consistent with a previous phase I study of cediranib monotherapy in Japanese patients and with studies of other targeted agents in Japanese patients with advanced cancer [30, 31] . Overall, no new safety issues were identified; no fatal AEs occurred and the AE profile was consistent with previous cediranib studies [10, 15] . With the exception of hypertension, diarrhoea, proteinuria, hypothyroidism, reversible posterior leukoencephalopathy syndrome, fatigue, hepatotoxicity, haematological toxicity and thrombocytopenia (for which specific management protocols were employed), cediranib-associated AEs were managed by dose interruption of up to 14 days or, if longer, treatment discontinuation. The incidences of grade ‡3 AEs and SAEs observed in this trial following addition of a TKI to FOLFOX therapy are consistent with those reported in trials involving vatalanib and bevacizumab in combination with a FOLFOX regimen [23, 32] . Cediranib treatment has shown a less favourable AE profile compared with bevacizumab in Western patients in the HORIZON III study [23] . In a phase I/II study in Japanese mCRC patients treated with XELOX plus bevacizumab, the most common grade 3/4 AEs were neurosensory toxicity (17%) and neutropenia (16%), both of which were managed by dose reduction of XELOX components; the incidence of grade 3/4 diarrhoea was only 3% [29] . It is not clear why the toxicity profiles of cediranib and bevacizumab differ, but it is probably related to differences in mechanism of action; cediranib is a potent inhibitor of the three VEGF receptor tyrosine kinases, whereas the activity of bevacizumab is dependent on preventing VEGF from binding to VEGF receptors, rather than blocking the receptors directly. In addition, the potential contribution of cediranib activity versus non-VEGFR kinases, e.g. c-Kit inhibition [33] , cannot be excluded. Furthermore, cediranib undergoes extensive metabolism, so it is possible that one or more metabolites may add to the toxicity profile.
An assessment of the levels of the soluble biomarkers VEGF and sVEGFR-2 was conducted as an exploratory objective. Owing to the limited data, caution should be taken when drawing conclusions from these findings; however, the observed increase in VEGF levels and decrease in sVEGFR-2 levels in cediranib-treated patients are consistent with previous cediranib trials [10, 21] . The increased VEGF levels may represent an acute stress response to inhibition of VEGF signalling by cediranib, whereas changes in sVEGFR-2 levels could be a surrogate marker for biological activity.
Analysis with an additional 8 months of follow-up data revealed similar findings to the pre-specified protocol analysis in both efficacy and safety outcomes. This additional analysis confirmed that PFS in this study (HR = 0.76) is consistent with the HORIZON II study (HR = 0.84), in which significantly improved PFS was observed with the addition of cediranib 20 mg to standard chemotherapy (FOLFOX/XELOX) [22] .
This study met its primary end point for improved PFS with cediranib 20 mg plus mFOLFOX6 compared with placebo plus mFOLFOX6. The outcomes from this study, and from HORIZON II [22] and HORIZON III [23] , provide some understanding of the potential role of VEGFR TKIs in the management of previously untreated mCRC. In unselected patient populations, cediranib provided marginal clinical benefit when added to standard oxaliplatin-based chemotherapy. These data did not support further development of cediranib in CRC; however, further investigation may reveal a particular benefit in a more selective patient population.
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